RET-targeting drug study for advanced cancers with RET changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (as defined by your local region’s rules).
- Your tumor must have a RET gene abnormality (found on biopsy tissue or a blood test).
- You have advanced or metastatic solid cancer, and at least some measurable tumor (or non-measurable disease the study allows).
- Your general fitness (“ECOG performance”) must be 0–1 for Phase 1 and 0–2 for Phase 2.
- Your liver, kidney, and blood counts must be adequate based on blood tests.
- If you have brain or covering-of-the-brain (“leptomeningeal”) metastases, you must be symptom-free and stable on medicines for at least 7 days (or already treated and stable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
This study tests a new drug called SNH-118110 in patients with advanced solid tumors that have a specific genetic change (RET alteration). The drug is designed to target and slow down cancer cells with this mutation. You may qualify if your cancer has this genetic change and standard treatments haven't worked or you couldn't tolerate them.
Hear when a new RET-altered Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.